In an unprecedented move by the University of Utah’s Huntsman Cancer Institute, a patient with blood cancer has received an allogeneic stem cell transplant with a twist: the procedure incorporated stem cells from a deceased donor. As reported by At the U, this marks a significant milestone in a clinical trial that could potentially expand treatment options for patients with various serious conditions, including aggressive blood cancers.
Principal investigator Sagar Patel, who is a key figure on the Blood and Marrow Transplantation team at Huntsman and an associate professor of medicine, articulated the importance of this breakthrough. "This study represents an exciting step toward improving transplant access for patients facing aggressive blood cancers like acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, and non-Hodgkin lymphoma," Patel said, as per At the U. The initiative was funded by the Center for the Biomedical Advanced Research and Development Authority and Ossium Health, to determine if pre-banked stem cells from deceased donors can be used safely and effectively.
Conventional stem cell transplants rely on finding living donors, which can be a challenge. Matches are often sought through family ties or volunteer registries, but for many patients, no suitable donor is found, or potential donors cannot participate. The current clinical trial is looking to ease this process by harvesting stem cells from the vertebral column of deceased donors who consented to organ donation. This might significantly cut down the wait times and uncertainties surrounding donor match and availability.
Patel highlighted the potential impact of this medical advancement. "We hope we have unlocked a resource that was previously untapped. By using the vertebral column's rich supply of stem cells, we aim to preserve them for future use, thereby improving the chances of finding a compatible match for more patients in need," Patel said, as obtained by At the U. Paramount to this trial's ambition is to establish deceased donor grafts as a feasible alternative which could benefit patients requiring immediate transplants.
